Early cannulation of the Flixene™ arteriovenous graft.

Ottaviani N; Deglise S; Brizzi V; Ducasse E; Midy D; Rigothier C; Saucy F; Berard X

doi:10.5301/jva.5000512

Back

Journal article

Early cannulation of the Flixene™ arteriovenous graft.

Ottaviani N Vascular Surgery Department, CHU de Bordeaux, Bordeaux - France.
Deglise S Vascular Surgery Department, Lausanne University Hospital, Lausanne - Switzerland.
Brizzi V Vascular Surgery Department, CHU de Bordeaux, Bordeaux - France.
Ducasse E Vascular Surgery Department, CHU de Bordeaux, Bordeaux - France.
Midy D Vascular Surgery Department, CHU de Bordeaux, Bordeaux - France.
Rigothier C University of Bordeaux, Faculty of Medicine, Bordeaux - France.
Saucy F Vascular Surgery Department, Lausanne University Hospital, Lausanne - Switzerland.
Berard X Vascular Surgery Department, CHU de Bordeaux, Bordeaux - France.

2016-03-09

Published in:

The journal of vascular access. - 2016

Blood Vessel Prosthesis Implantation

English PURPOSE
The aim of this review was to search for evidence of the efficiency of early cannulation of the Flixene™ (Maquet-Atrium Medical, Hudson, NH, USA) arteriovenous graft (AVG) in the current literature and to assess its patency and complication rates.

METHODS
Searches in Pubmed, Medline, Embase and the Cochrane Library were performed using the following specific search terms: early cannulation AVG and/or Flixene™ graft. The primary outcomes were mean time to first cannulation and patency rates at 12 months. Secondary outcomes were complications.

RESULTS
Six studies reporting outcomes in a total of 260 procedures were included in this review. The median delay from intervention to first cannulation was documented in four studies and was less than 3 days. Primary assisted patency at 12 months ranged from 45% to 53% in the four documented series. In five studies, documented secondary patency at 12 months ranged from 63% to 92%. Two studies compared outcomes between traditional and Flixene™ grafts: one study reported significantly (p<0.01) improved one-year patency using the Flixene™ graft, the two studies did not report significant differences in complication rates between both groups. The rate of infection and pseudo-aneurysm formation ranged from 0 to 11% and 0 to 6%, respectively.

CONCLUSIONS
This review shows that early cannulation of the Flixene™ graft within 3 days following its implantation is feasible with one-year patency and complication rates equivalent to those of conventional grafts which can be cannulated only after 2 weeks.

Language